MTR Gene Methylcobalamin Deficiency (CblG Type) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MTR (نقص ميثيل كوبالامين من نوع CblG) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited processing (Cert. INT/EGQ/2509DA/3139).
- Premium Logistics – Hospital‑grade cold‑chain home collection & VIP mobile phlebotomy (8 AM‑11 PM).
- Post‑Test Clinical Guidance – Telephonic result interpretation by qualified professionals.
- Direct Billing & Insurance – WhatsApp verification +971 54 548 8731.
خلاصة تنفيذية: فحص تسلسل الجيل التالي لجين MTR يوفر أعلى درجات الدقة وفقًا لأعلى معايير الجودة العالمية، مع خدمة سحب منزلي متميزة ودعم استشاري فوري عبر الواتساب.
Test Overview
The MTR gene NGS test sequences the entire coding region of the MTR gene, detecting pathogenic variants responsible for methylcobalamin deficiency CblG type—a treatable inborn error of vitamin B12 metabolism that can cause neonatal encephalopathy, developmental delay, and later‑onset neurological decline. يقدم هذا الفحص الشامل تحليلاً دقيقاً للجين MTR باستخدام تقنية الجيل التالي (NGS)، مما يساعد الأطباء في التشخيص المبكر ووضع خطة علاجية مخصصة تمنع المضاعفات الخطيرة.
| Feature | Our Test – MTR NGS | Biochemical Homocysteine/MMA |
|---|---|---|
| Methodology | Illumina NGS (full gene sequencing, 100× coverage) | LC‑MS/MS for homocysteine & methylmalonic acid |
| Analytical Sensitivity | 99.9% (single nucleotide variants, indels) | High for functional defect, no genotyping |
| Turnaround Time | 3–4 Weeks | 1–2 Days |
| Diagnostic Value | Definitive molecular diagnosis, carrier screening | Preliminary screening, monitoring treatment |
Clinical Guidance from Dr. Prabhakar Reddy
“As a clinician, I deeply empathise with families confronting the uncertainty of a genetic metabolic disorder. This NGS test provides unambiguous molecular answers, yet I always stress that every result must be interpreted alongside your full clinical picture and detailed family history. It is a life‑altering tool that, when used wisely, allows us to tailor treatment and offer precise genetic counselling.”
Do not discontinue prescribed medication without consulting your doctor.
Safety Protocol & Exclusion Criteria
- Unstable acute condition: Do not proceed if the patient has a febrile illness, acute haemolytic anaemia, or received blood transfusion within the last 14 days (risk of sample contamination).
- Neonatal emergency: Infants with suspected metabolic crisis (lethargy, poor feeding, hypotonia) must be stabilised in an emergency setting before sample collection.
- Immediate red flags: If the patient develops seizures, loss of consciousness, respiratory distress, or acute psychosis, skip the test and seek ER care.
Frequently Asked Questions
1. What is the MTR gene methylcobalamin deficiency CblG type test?
This NGS test sequences the entire MTR gene to identify disease‑causing mutations, providing a definitive molecular diagnosis for cblG‑type methylcobalamin deficiency. هو فحص جيني متقدم يحدد الطفرات المسببة لنقص ميثيل كوبالامين بدقة، مما يؤكد التشخيص ويوجه العلاج الشخصي.
2. How is the sample collected, and what preparation is required?
A simple blood draw (EDTA tube), or a single drop of blood on an FTA card, is all that’s needed—no fasting or medication changes are required for DNA analysis. عينة دم بسيطة أو قطرة واحدة على بطاقة FTA تكفي، ولا يلزم الصيام أو إيقاف الأدوية.
3. How long do results take, and do I need a referral?
Results are available in 3 to 4 weeks; a doctor’s referral is mandatory for pre‑ genetic counselling and insurance billing. تصدر النتائج خلال 3 إلى 4 أسابيع، ويشترط تحويل طبي لجلسة الاستشارة الوراثية والموافقة المستنيرة.